文献速递外周动脉疾病

需膝下干预的慢性肢体威胁性缺血患者的外科手术或血管内治疗

Surgery or endovascular therapy for patients with chronic limb-threatening ischemia requiring infrapopliteal interventions.
PubMed 文献 · J Vasc Surg · 2024-06-21

该研究基于BEST-CLI试验中665例有合适单段大隐静脉且存在显著膝下病变并接受胫动脉水平干预的患者,比较开放胫动脉旁路手术与胫动脉血管内干预的结局。3年主要不良肢体事件或全因死亡在手术组为48.5%,低于血管内组的56.7%(P=0.0018)。作者结论认为开放旁路手术与较低的主要不良肢体事件或死亡发生率及较少的重大截肢相关,无截肢生存率两组相似。

要点

  • 在BEST-CLI队列1的665例膝下病变患者中,3年主要不良肢体事件或全因死亡手术组48.5% vs 血管内组56.7%(P=0.0018)。
  • 主要不良肢体事件手术组23.3% vs 血管内组35.0%(P<0.0001),其中重大再干预手术组10.9% vs 血管内组20.2%(P=0.0006)。
  • 全因死亡手术组35.5% vs 血管内组35.8%(P=0.94),无踝上截肢或全因死亡生存率手术组43.6% vs 血管内组45.3%(P=0.30)。

核心结论

  • 在因慢性肢体威胁性缺血接受膝下血运重建且有合适单段大隐静脉的患者中,开放旁路手术与较低的主要不良肢体事件或死亡发生率及较少的重大截肢相关。
  • 两组无截肢生存率相似。
  • 需要进一步研究合并症、解剖范围和病变复杂性的差异,以解释BEST-CLI与BASIL-2报告的结局差异。

研究设计与样本

  • 本研究为BEST-CLI试验中队列1患者的分析,纳入有合适单段大隐静脉、随机分配至开放旁路或血管内干预、且存在显著膝下病变并接受胫动脉水平干预的患者。
  • 分析子组共665例患者,其中开放胫动脉旁路组326例,胫动脉血管内干预组339例。
  • 主要结局为主要不良肢体事件或全因死亡,主要不良肢体事件包括任何重大截肢或重大再干预,采用Cox比例回归模型评估结局。

主要发现

  • 3年主要不良肢体事件或全因死亡手术组为48.5%,血管内组为56.7%(P=0.0018),手术组显著较低。
  • 全因死亡手术组35.5% vs 血管内组35.8%(P=0.94),两组相似。
  • 主要不良肢体事件手术组23.3% vs 血管内组35.0%(P<0.0001),手术组较低。
  • 重大再干预手术组10.9% vs 血管内组20.2%(P=0.0006),手术组较低。
  • 无踝上截肢或全因死亡生存率手术组43.6% vs 血管内组45.3%(P=0.30),两组相似;踝上截肢手术组13.5% vs 血管内组19.3%(P=0.0205),手术组较少。

关键数值与推荐

  • 围手术期(30天)死亡手术组2.5% vs 血管内组2.4%(P=0.93),两组相似。
  • 30天主要不良心血管事件手术组5.3% vs 血管内组2.7%(P=0.12),两组相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要进一步研究合并症、解剖范围和病变复杂性的差异,以解释BEST-CLI与BASIL-2报告的结局差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The recent publication of randomized trials comparing open bypass surgery to endovascular therapy in patients with chronic limb-threatening ischemia, namely, Best Endovascular vs Best Surgical Therapy in Patients with Critical Limb Ischemia (BEST-CLI) and Bypass versus Angioplasty in Severe Ischaemia of the Leg-2 (BASIL-2), has resulted in potentially contradictory findings. The trials differed significantly with respect to anatomical disease patterns and primary end points. We performed an analysis of patients in BEST-CLI with significant infrapopliteal disease undergoing open tibial bypass or endovascular tibial interventions to formulate a relevant comparator with the outcomes reported from BASIL-2. METHODS: The study population consisted of patients in BEST-CLI with adequate single segment saphenous vein conduit randomized to open bypass or endovascular intervention (cohort 1) who additionally had significant infrapopliteal disease and underwent tibial level intervention. The primary outcome was major adverse limb event (MALE) or all-cause death. MALE included any major limb amputation or major reintervention. Outcomes were evaluated using Cox proportional regression models. RESULTS: The analyzed subgroup included a total of 665 patients with 326 in the open tibial bypass group and 339 in the tibial endovascular intervention group. The primary outcome of MALE or all-cause death at 3 years was significantly lower in the surgical group at 48.5% compared with 56.7% in the endovascular group (P = .0018). Mortality was similar between groups (35.5% open vs 35.8% endovascular; P = .94), whereas MALE events were lower in the surgical group (23.3% vs 35.0%; P<.0001). This difference included a lower rate of major reinterventions in the surgical group (10.9%) compared with the endovascular group (20.2%; P = .0006). Freedom from above ankle amputation or all-cause death was similar between treatment arms at 43.6% in the surgical group compared with 45.3% the endovascular group (P = .30); however, there were fewer above ankle amputations in the surgical group (13.5%) compared with the endovascular group (19.3%; P = .0205). Perioperative (30-day) death rates were similar between treatment groups (2.5% open vs 2.4% endovascular; P = .93), as was 30-day major adverse cardiovascular events (5.3% open vs 2.7% endovascular; P = .12). CONCLUSIONS: Among patients with suitable single segment great saphenous vein who underwent infrapopliteal revascularization for chronic limb-threatening ischemia, open bypass surgery was associated with a lower incidence of MALE or death and fewer major amputation compared with endovascular intervention. Amputation-free survival was similar between the groups. Further investigations into differences in comorbidities, anatomical extent, and lesion complexity are needed to explain differences between the BEST-CLI and BASIL-2 reported outcomes.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Giles KA, Farber A, Menard MT, et al. Surgery or endovascular therapy for patients with chronic limb-threatening ischemia requiring infrapopliteal interventions. J Vasc Surg. 2024. PMID: 38908805. doi:10.1016/j.jvs.2024.05.049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。